RYVU THERAPEUTICS S.A.
H1 2026 Report

TABLE OF CONTENTS

1. ECONOMIC AND FINANCIAL HIGHLIGHTS

1.1 Financial results obtained in the reporting period

Condensed Interim Financial Statements of Ryvu Therapeutics S.A. (“Company”, “Issuer”, “Ryvu”) for the period from January 1, 2026, to June 30, 2026, are prepared in accordance with the requirements of the International Accounting Standard No. 34 "Interim Financial Reporting" endorsed by the EU ("IAS 34").

Selected data of the statement of financial position are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand		Data in EUR thousand	
Item	**30.06.2026**	31.12.2025	**30.06.2026**	31.12.2025
Total assets	**182,560**	224,436	**42,492**	53,100
Short-term receivables	**14,271**	20,100	**3,322**	4,756
Cash and cash equivalents	**50,661**	59,606	**11,792**	14,102
Other current and non-current financial assets	**24,080**	48,072	**5,605**	11,373
Total liabilities	**154,186**	170,601	**35,888**	40,363
Long-term liabilities	**108,491**	109,020	**25,252**	25,793
Short-term liabilities	**45,696**	61,581	**10,636**	14,569
Total equity	**28,374**	53,834	**6,604**	12,737
Share capital	**9,248**	9,248	**2,153**	2,188

Selected data of the statement of comprehensive income are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand				Data in EUR thousand			
Item	**From 01.01.2026 to 30.06.2026**	From 01.01.2025 to 30.06.2025	**From 01.04.2026 to 30.06.2026**	From 01.04.2025 to 30.06.2025	**From 01.01.2026 to 30.06.2026**	From 01.01.2025 to 30.06.2025	**From 01.04.2026 to 30.06.2026**	From 01.04.2025 to 30.06.2025
Revenues from sales	**22,497**	22,912	**9,060**	9,493	**5,291**	5,428	**2,126**	2,230
Revenues from subsidies	**9,724**	13,090	**4,964**	8,989	**2,287**	3,101	**1,165**	2,112
Revenues from R&D projects	**6,442**	6,424	**2,928**	2,910	**1,515**	1,522	**687**	684
Other operating revenues	**0**	5	**0**	3	**0**	1	**0**	1
Revenues from operating activities	**38,662**	42,432	**16,952**	21,395	**9,092**	10,053	**3,977**	5,026
Operating expenses	**-67,511**	-107,796	**-33,640**	-49,068	**-15,877**	-25,539	**-7,892**	-11,527
Operating expenses without Incentive Scheme and valuation of Nodthera shares	**-67,560**	-95,542	**-33,582**	-47,742	**-15,888**	-22,636	**-7,878**	-11,215
Depreciation	**-4,147**	-4,718	**-2,000**	-2,295	**-975**	-1,118	**-469**	-539
Valuation of Incentive Scheme	**-244**	-1,882	**-105**	-887	**-57**	-446	**-25**	-208
Loss from operating activities (EBIT)	**-28,849**	-65,364	**-16,688**	-27,674	**-6,784**	-15,486	**-3,915**	-6,501
Loss from operating activities (EBIT) without Incentive Scheme and valuation of Nodthera shares	**-28,897**	-53,111	**-16,630**	-26,348	**-6,796**	-12,583	**-3,901**	-6,190
Loss before income tax	**-25,369**	-58,917	**-12,902**	-33,655	**-5,966**	-13,959	**-3,027**	-7,906
Net loss	**-25,705**	-58,934	**-13,057**	-33,658	**-6,045**	-13,963	**-3,063**	-7,907
Net loss without Incentive Scheme	**-25,461**	-57,052	**-12,953**	-32,771	**-5,988**	-13,517	**-3,039**	-7,256
EBITDA	**-24,702**	-60,646	**-14,689**	-25,378	**-5,809**	-14,368	**-3,446**	-5,820
EBITDA without Incentive Scheme and valuation of Nodthera shares	**-24,750**	-48,392	**-14,630**	-24,052	**-5,821**	-11,465	**-3,432**	-5,509
Net cash flows from operating activities	**-32,466**	-68,590	**-9,622**	-24,407	**-7,635**	-16,251	**-2,257**	-5,734
Net cash flows from investing activities	**26,035**	18,185	**10,535**	-18,979	**6,123**	4,308	**2,472**	-4,459
Net cash flows from financing activities	**-2,297**	-2,170	**-1,102**	-852	**-540**	-514	**-259**	-200
Total net cash flow	**-8,727**	-52,576	**-189**	-44,239	**-2,052**	-12,456	**-44**	-10,393
Number of shares (weighted average)	**23,120,148**	23,120,148	**23,120,148**	23,120,148	**23,120,148**	23,120,148	**23,120,148**	23,120,148
Profit (loss) per share (in PLN)	**-1.11**	-2.55	**-0.56**	-1.46	**-0.26**	-0.60	**-0.13**	-0.34
Diluted profit (loss) per share (in PLN)	**-1.11**	-2.55	**-0.56**	-1.46	**-0.26**	-0.60	**-0.13**	-0.34
Book value per share (in PLN)	**1.23**	4.12	**1.23**	4.12	**0.29**	0.97	**0.29**	0.97
Diluted book value per share (in PLN)	**1.23**	4.12	**1.23**	4.12	**0.29**	0.97	**0.29**	0.97
Declared or paid dividend per share (in PLN)	**-**	-	-	-	-	-	-	

Selected financial data presented in the Quarterly report were converted to Euro as follows:

1. Items relating to the profit and loss statement and the cash flow statement were converted using the exchange rate constituting the arithmetic average of the exchange rates, applicable as of the last day of every month in the given period, based on the information published by the National Bank of Poland (NBP):
   - for the period from 01/01/2026 – 30/06/2026: PLN 4.2522
   - for the period from 01/01/2025 – 30/06/2025: PLN 4.2208;
2. Balance sheet items were converted using the average exchange rate announced by the NBP applicable as of the balance sheet date, which were:
   - as of 30 June 2026: PLN 4.2963;
   - as of 31 December 2025: PLN 4.2267.

1.2 Management Board comments on the financial results

In the first half of 2026, Ryvu Therapeutics S.A. recognized total operating revenue of PLN 38,662 thousand, which constitutes a decrease compared to the corresponding period in 2025, when total operating revenue amounted to PLN 42,432 thousand. This results from a decrease in revenues from subsidies (a decrease of PLN 3,366 thousand) and decrease in revenues from sales (a decrease of PLN 415 thousand), partially compensated by an increase in revenues from R&D projects (an increase of PLN 18 thousand) compared to the corresponding period in 2025.

In the first half of 2026, Ryvu reported a net loss, as well as an operating loss. The net and operating losses result from the fact that the Company focuses on increasing the value of the ongoing projects that will be commercialized at a later stage of development.

The Company's net loss for the period ended June 30, 2026, amounted to PLN 25,705 thousand and was lower compared to the net loss of PLN 58,934 thousand in the corresponding period of 2025. The Company's operating loss without Incentive Scheme and valuation of Nodthera shares in H1 2026 decreased by PLN 24,213 thousand compared to the corresponding period of 2025 from PLN 53,111 thousand in H1 2025 to PLN 28,897 thousand in H1 2026. Operating costs without Incentive Scheme and valuation of Nodthera shares decreased from PLN 95,542 thousand in H1 2025 to PLN 67,560 thousand in H1 2026.

The improvement was particularly visible in Q2 2026, when the Company's net loss decreased by 61% year on year, from PLN 33,658 thousand to PLN 13,057 thousand, primarily reflecting lower expenditure on research and clinical development programs following the strategic prioritization of the portfolio.

The reduction in operating costs reflects a deliberate concentration of resources on the programs with the highest near-term value-creation potential, principally the RIVER-81 Phase II study of romaciclib in relapsed/refractory AML following venetoclax-based therapy failure — a setting with no approved therapeutic option and a median overall survival of under three months. This focus is expected to accelerate the generation of clinical evidence required to conclude partnering agreement and further program development. Furthermore, the Company continues to maintain cost discipline following the strategic reorganization announced in February 2025.

Valuation of shares in NodThera Inc.

The Company holds shares in NodThera Inc., a biotechnology company developing NALP3 inhibitors for the treatment of inflammatory and neuroinflammatory diseases.

On July 15, 2026, NodThera Inc. issued Series D4 Preferred Stock. The offering comprised 16,389,452 shares at a price of USD 0.9259 per share. As a result, NodThera received total financing of USD 15,174,993.66. The offering was made exclusively to existing investors. Series D shares carry the same preferential rights as Series A, B, and C shares. Ryvu did not participate in this financing round.

Therefore, the valuation was based on a share price of USD 0.9259 per share, corresponding to the price of the Series D4 shares in the most recent financing round completed on July 15, 2026.

As of June 30, 2026, Ryvu held 1.2% shares in NodThera. Following the Series D4 issuance, Ryvu's shareholding decreased to 1.06%, and the total valuation of its stake amounts to PLN 6,668,543 (based on the NBP's average exchange rate of 3.7708 PLN/USD).

Financing from the European Investment Bank

On August 16, 2022, the Company concluded a financing agreement with the European Investment Bank ("EIB"). Under the agreement, the EIB agreed to grant the Company a loan in the maximum amount of EUR 22,000,000.

The financing was paid in three tranches. The Company is obliged to repay each of the paid tranches in one installment in 2029, 5 years after its launch.

In consideration for the financing received, the Company issued to the EIB subscription warrants representing in aggregate 2.5% of the Company's fully issued share capital. The Company undertook to issue 592,825 subscription warrants to the EIB.

Additionally, put option issued by the Company creates a contractual obligation to repurchase its equity instruments (warrants). As of June 30, 2026, Ryvu recognized a positive impact of the put option in the amount of PLN 7,408 thousand.

1.3 The Company’s Assets and the Structure of Assets and Liabilities

As of June 30, 2026, the value of the Company’s assets was PLN 182,560 thousand and decreased by PLN 41,876 thousand compared to the end of 2025 (PLN 224,436 thousand), mainly due to expenditures incurred on discovery and clinical projects. At the end of June 2026, the highest value of assets was cash, which amounted to PLN 50,661 thousand (at the end of 2025, it was PLN 59,606 thousand) together with other financial assets of PLN 24,080 thousand (at the end of 2025, it was PLN 48,072 thousand). Fixed assets are mainly the Research and Development Centre for Innovative Drugs (named ‘CBR’) and laboratory equipment, as well as the valuation of NodThera shares.

The main item in Ryvu’s equity and liabilities is equity, which amounted to PLN 28,374 thousand as of June 30, 2026, and decreased by PLN 25,461 thousand compared to December 31, 2025. The decrease in equity is primarily attributable to the net loss recorded for the period. The other source of funding for assets is long-term liabilities, which amounted to PLN 108,491 thousand as of the end of June 2026. The long-term liabilities are mainly related to the loan received from the European Investment Bank. Additionally, long-term liabilities include deferred income, primarily related to deferred revenue from the BioNTech agreement, as well as the infrastructure subsidy for CBR.

The asset structure demonstrates the Company's high financial liquidity, which is confirmed by the following ratios:

	30.06.2026	31.12.2025
Current ratio current assets/current liabilities including short-term provisions and accruals (excl. deferred revenues)	2.35	2.74
Quick ratio (current assets-inventory)/current liabilities including short-term provisions and accruals (excl. deferred revenues)	2.32	2.73

Cash surpluses, not used in the operating activities, are deposited in low-risk financial instruments like short- and long-term bank deposits and bonds.

1.4 Current and Projected Financial Condition

The Company maintains adequate liquidity to fund its planned operations, supported by its current cash position and the financing received from the European Investment Bank. The Company continues to evaluate additional non-dilutive financing options to support the clinical development of romaciclib and other pipeline programs.

As of June 30, 2026, the value of the Company's cash amounted to PLN 74,741 thousand (PLN 50,661 thousand in cash at the banks, PLN 24,080 thousand in investment funds), and as of September 10, 2026, it was PLN 62,092 thousand (PLN 37,972 thousand in cash at the banks and PLN 24,120 thousand investment funds). The decrease in cash resulted from expenditure incurred on early pipeline and clinical development projects.

Ryvu continues to advance three key strategic collaborations, under which all incurred costs are fully reimbursed, and the Company remains eligible to receive multiple financial milestones: Menarini, relating to JASPIS-01; BioNTech, relating to discovery programs; and Exelixis, relating to STING-agonist-based ADCs.

These partnerships are important because they provide validation of Ryvu's scientific platform, reduce internal funding requirements, and create the potential for milestone-driven upside.

In parallel, Ryvu continues to engage with potential partners for its fully owned programs.

Ryvu is also continuing to build Keelira, its dedicated early clinical development services business launched in August 2026 (described in more detail below), which commercializes clinical development capabilities developed on Ryvu's own oncology pipeline and already applied in external clinical collaborations. The Company expects Keelira to generate a growing, capital-efficient complementary revenue stream as its client portfolio expands, alongside Ryvu's own oncology pipeline, which remains its strategic priority.

Cash inflow from previous share issues, funds obtained from EU subsidies, financing received from the EIB, funds supporting R&D projects, and cash generated from the commercialization of projects enable the Company to execute its planned investments, particularly the development of ongoing and new innovative projects and the expansion of laboratory infrastructure. The Company's future revenues will strongly depend on the ability to commercialize its R&D projects.

The Company may obtain additional non-dilutive financing from multiple sources, among others:

- potential strategic and financial partners,
- financial milestones and research funding from current collaborations,
- new projects with current and new partners, including new clients of Keelira, the Company's clinical services business.

2. MANAGEMENT BOARD INFORMATION ON ACTIVITES

2.1 The pipeline

Ryvu Therapeutics is advancing a broad pipeline addressing emerging targets in oncology.

Ryvu's pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinases, synthetic lethality, immuno-oncology and immunometabolism pathways. These research and development projects are represented below.



Source: Company's own data.

Romaciclib (RVU120)

Romaciclib (RVU120) is a clinical-stage, selective, first-in-class dual inhibitor of CDK8 and CDK19 kinases. The international nonproprietary name of romaciclib was assigned to RVU120 by the WHO and announced on the proposed list in February 2025, followed by the publication of the INN Recommended List 94 on November 3, 2025. Romaciclib has demonstrated efficacy in several solid tumors and hematologic malignancies in *in vitro* and *in vivo* models. CDK8 and its paralog, CDK19, are kinase submodules of the mediator complex, involved in both transcriptional activation and repression, playing central roles in maintaining the viability of cancer cells and their undifferentiated state across various tumor types (Dannappel et al., 2019; Rzymski et al., 2015; Philip et al., 2018). CDK8/19 mediator complex integrates basal transcriptional machinery with the activity of oncogenic transcriptional and epigenetic factors. Inhibition of CDK8/19 can repress key oncogenic transcriptional programs and induce lineage commitment genes in acute myeloid leukemia (AML).

Romaciclib has been internally discovered by Ryvu and has received support from the Leukemia & Lymphoma Society Therapy Acceleration Program® (TAP; the organization has operated as Blood Cancer United since August, 2025), a strategic initiative to partner directly with innovative biotechnology companies and leading research institutions to accelerate the development of promising new therapies for blood cancers.

On March 25, 2020, the U.S. Food and Drug Administration (FDA) granted romaciclib an orphan drug designation (ODD) for the treatment of patients with AML.

Based on the available translational and clinical data, Ryvu is executing a Clinical Development Plan (CDP) for romaciclib with focus on hematologic malignancies.

Five clinical studies with romaciclib have ended enrollment and all patients have discontinued study treatment: (i) Phase Ib in patients with AML/HR-MDS (NCT04021368; CLI120-001, RIVER-51), (ii) Phase I/II in patients with relapsed/refractory metastatic or advanced solid tumors (NCT05052255; RVU120-SOL-021, AMNYS-51), (iii) Phase II in patients with AML/ HR-MDS (NCT06268574; RIVER-52), (iv) Phase II in patients with intermediate or high-risk, primary or secondary myelofibrosis (NCT06397313, POTAMI-61), (v) Phase II in patients with lower risk myelodysplastic neoplasms (NCT06243458, REMARK).

Two clinical studies reported preliminary results during the reporting period.

RIVER-81 Phase II study

On January 31, 2024, Ryvu announced the dosing of the first patient in the RIVER-81 Phase II study of romaciclib in combination with venetoclax (NCT06191263). RIVER-81 is a multicenter, open-label clinical trial that aims to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of romaciclib when administered in combination with venetoclax to patients with AML who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent.

Ryvu Therapeutics reported a clinical data update at the European Hematology Association (EHA) Congress in June 2026 in Stockholm, Sweden. The poster presented longer follow-up data. At the 150 mg QD + VEN 400 mg dose level, the composite CR/CRi rate was 43% (3/7), including two complete remissions with (CR) and one without (CRi) full hematologic recovery. Across other dose levels, 6 CRh/CRi responses were reported in 51 treated patients. The mean duration of response (DoR) of the CRs was 156 days, reported with a cut-off date of 12 May 2026.

On January 13, 2026, a Type C meeting was held with the U.S. Food and Drug Administration (FDA) regarding the development of romaciclib (RVU120) in combination with venetoclax for patients with relapsed or refractory acute myeloid leukemia following failure of venetoclax plus a hypomethylating agent. This indication is currently being evaluated in the RIVER-81 study. The FDA raised no objections to opening the U.S. expansion cohort and provided guidance on dose optimization, the expected use of integrated safety, pharmacokinetic and pharmacodynamic data, and general considerations for future registrational study design, including the role of randomization in combination therapy studies. Following completion of the required regulatory steps, including an updated RIVER-81 study protocol and submission of documentation under the existing IND, the IND for the RIVER-81 study was re-activated on May 28, 2026. Once more mature clinical data from the expansion stage are available, Ryvu intends to seek further FDA feedback on the potential registration pathway for romaciclib in this setting.

As reported by the Company in current report no. 9/2026 dated May 20, 2026, Ryvu is initiating an expansion cohort in the RIVER-81 trial, comprising approximately 30 patients with relapsed or refractory AML, to confirm the positive efficacy demonstrated in the 150 mg once-daily dose cohort of romaciclib in combination with 400 mg once-daily venetoclax. In Europe, the updated RIVER-81 protocol, reflecting feedback received during the FDA meeting, has been approved through CTIS, with approval granted on July 31, 2026, enabling initiation of the expansion cohort in European countries. Following this approval, Ryvu is proceeding with site initiation and patient enrolment activities. The first patient in the new cohort was dosed on August 26, 2026.

The execution of the RIVER-81 study is supported by a PLN 62.3 million grant from the Polish Medical Research Agency (ABM).

POTAMI-61 Phase II study

The Phase II POTAMI-61 study (NCT06397313) investigates romaciclib as both a monotherapy and a combination therapy for treating patients with myelofibrosis (MF). In Part A, Cohort 1 assesses romaciclib as a monotherapy in patients who have been previously treated with or are ineligible for treatment with a JAK inhibitor, and Cohort 2 assesses romaciclib in combination with ruxolitinib in patients experiencing a suboptimal response to JAK inhibitor therapy.

Romaciclib's potential in myelofibrosis is supported by its effect on bone marrow and hematopoietic cells observed in the clinical trial setting, as well as in translational data generated with Prof. Raajit Rampal at the Memorial Sloan Kettering Cancer Centre as part of a collaboration with Ryvu established in 2021. It was demonstrated that romaciclib successfully attenuates myelofibrosis phenotypes, either as a single agent or in combination with ruxolitinib, in murine models of myelofibrosis. Furthermore, romaciclib was shown to act synergistically with a whole class of JAK inhibitors and the BET inhibitor pelabresib.

The POTAMI-61 study was launched at clinical sites in Poland and Italy, and on December 5, 2024, the first patient received treatment.

A clinical data update was presented at the European Hematology Association (EHA) Congress in June 2026 in Stockholm, Sweden. In the Phase II POTAMI-61 study, romaciclib administered as monotherapy or combined with ruxolitinib demonstrated a manageable safety profile in patients with MF without significant treatment-related cytopenias. Prolonged exposure, spleen volume reductions, including in patients with high-molecular-risk mutations, and favorable hematologic tolerability support continued clinical development.

Following the completion of Part A (23 patients) of the study and initial enrollment in Part B (5 patients), Management Board of the Company has decided not to proceed with further enrollment, closing the study at 28 patients. The decision to discontinue enrolment was not based on any safety concerns. Eight patients were transferred into the ROVER-01 rollover study, underscoring that a subset of patients continue to derive meaningful clinical benefit from romaciclib treatment. These patients will continue to receive treatment with romaciclib as long as they benefit from romaciclib according to investigators' assessment The Company will analyze data from POTAMI-61 to inform potential future myelofibrosis development decisions and retain the option to resume a modified myelofibrosis development.

MEDWAY Phase I study

Additionally, an investigator-initiated Phase I study to evaluate romaciclib in combination with everolimus in pediatric patients with medulloblastoma (MEDWAY) was announced in September 2025. The MEDWAY project will be executed by the Children's Memorial Health Institute (IPCZD) as a sponsor of the study under an approx. PLN 40 million grant awarded by the Polish Medical Research Agency. The study was launched in August 2026. Romaciclib's development in a pediatric indication may qualify for a Rare Pediatric Disease Priority Review Voucher (PRV) or other incentive from the U.S. Food and Drug Administration upon regulatory approval.

Dapolsertib (MEN1703, SEL24)

Dapolsertib (also known as MEN1703 or SEL24) is a selective, small-molecule dual inhibitor of PIM and FLT3 kinases, two enzymes strongly implicated in the malignant transformation of hematopoietic cells and lymphomagenesis. The compound has been discovered by Ryvu and is currently in clinical development in collaboration with Menarini Group as a therapeutic option for various cancers. The licensing agreement with Menarini was executed in March 2017. Initially, dapolsertib was developed as a potential treatment for patients with relapsed/refractory acute myeloid leukemia (AML). More details of the completed Phase I/II clinical study are available at ClinicalTrials.gov under the identifier NCT03008187. Data from this part of the study were presented at multiple scientific conferences and symposia. Ryvu has been supporting this project with translational research.

Based on a decision announced in September 2023, Menarini has continued the development of dapolsertib by initiating a new Phase II study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) – JASPIS-01 study. Menarini fully funds all study activities, while Ryvu acts as the operational partner to execute the JASPIS-01 study on behalf of Menarini. The licensing partnership with Menarini, including the total milestones and royalties due to Ryvu upon the achievement of certain events, remains unchanged.

The JASPIS-01 study is an open-label, Phase II clinical trial investigating dapolsertib as a monotherapy and in combination with glofitamab for patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). It comprises three parts: Part 1 focuses on evaluating safety and preliminary anti-lymphoma activity in approximately 18 patients; Part 2, based on Part 1 results, will assess anti-tumor activity as a primary objective in a larger group of patients, as well as safety and tolerability; and Part 3 will offer an optional randomized comparison.

The JASPIS-01 study was initiated in Q4 2024. On March 26, 2025, Ryvu announced dosing of the first patient. The study was initiated at clinical sites in Poland. It is also currently recruiting in France, Spain, and the United Kingdom. The study is registered on ClinicalTrials.gov under NCT06534437. At the ASH Annual Meeting in December 2025, a Trial-in-Progress poster was presented. At this time, 11 patients had been enrolled across the combination and monotherapy cohorts.

On July 22, 2026, Ryvu concluded an amendment to its global license agreement with Menarini Group concerning the further clinical development of dapolsertib by initiating a new clinical study in patients with myelofibrosis (MF), a rare hematological malignancy, based on preclinical data indicating activity of dapolsertib in MF models. Ryvu acts as the study sponsor and will be responsible for the operational conduct of the study on behalf of Menarini Group, while Menarini will fund the activities covered by the amendment. This Phase II clinical study, SPHENE-01, will investigate dapolsertib primarily as

monotherapy in patients with myelofibrosis. The study is expected to be conducted in Europe and initiated in Q1 2027.

BioNTech: Clinical collaboration

In September 2025, Ryvu concluded a strategic agreement with BioNTech to provide specialized services to accelerate site activation and patient enrolment for several of BioNTech's priority oncology clinical programs in Poland, covering indications such as lung, breast, and colorectal cancers. Under the agreement, both parties leverage Ryvu's operational excellence, extensive expertise in oncology clinical operations, and established trial site network to enhance and streamline access for Polish patients to BioNTech's investigational immunotherapies.

PRECLINICAL AND DISCOVERY STAGE PROJECTS

Synthetic lethality projects

RVU305 Oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor in IND/CTA-enabling studies

RVU305 is a potentially best-in-class, oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor, currently in the IND/CTA-enabling phase. It is designed to target cancers characterized by the deletion of the MTAP metabolic gene, a genetic alteration found in approximately 10–15% of all human tumors. RVU305 leverages this vulnerability as an MTA-cooperative PRMT5 inhibitor, selectively impeding the growth of cancer cells harboring MTAP deletions.
In H1 2026, RVU305 achieved key preclinical milestones, including completion of toxicology studies and API/IMP manufacturing. Non-clinical GLP-toxicology studies were completed in two species with a favorable safety profile and no major toxicology findings; these data will inform the calculation of the first-in-human (FIH) starting dose. In parallel, synthesis of a GMP batch as well as manufacturing of the final clinical-trial drug product were completed.

Stability studies for the clinical drug product are ongoing in accordance with the established stability program and applicable ICH guidelines. Data generated to date support the required quality attributes of the drug product under the tested storage conditions, while additional stability time points are being collected to further characterize its stability profile. Building on these results, Ryvu is currently preparing the documentation package required for the submission of a Clinical Trial Application (CTA) to the relevant Regulatory Authority, subject to securing a development partnership.

Novel Multi-Target Discovery

ONCO Prime –Novel Small Molecule Precision Oncology

In addition to our disclosed projects, Ryvu is accelerating internal initiatives aimed at identifying and validating novel oncology targets for first-in-class small-molecule drug discovery projects. The ONCO Prime platform underpins this effort, generating new functional readouts that inform target prioritization and downstream drug discovery. Grant funding supports the platform's ongoing development, including expansion of the primary biobank and advancement of target discovery efforts in cancers with the highest population burden — colorectal cancer, lung adenocarcinoma, and triple-negative breast cancer (TNBC).

During H1 2026, Ryvu advanced multiple ONCO Prime programs, delivering new target discoveries in colorectal cancer and progressing the corresponding drug discovery efforts. In parallel, novel ONCO Prime targets were further characterized within the PERO program using a novel base-editing tiling approach, which enabled identification of functional pockets in targets with first-in-class potential. These findings are now guiding the design and development of small-molecule inhibitors — accelerating the drug discovery process and supporting the team's progress toward key project milestones.

Recent progress on the ONCO Prime platform was presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego and the 3rd CRISPR MEDiCiNE Conference in Copenhagen, both in April 2026. Poster presentations from these conferences are available on the company website: https://ryvu.com/investors-media/publications/.

ADC – Novel ADC payloads

Ryvu is strengthening its position in the field of small-molecule active payloads for antibody-drug conjugates (ADCs), advancing an internal portfolio of compounds and conjugation technologies designed to offer a genuine alternative to conventional ADCs based on classical cytotoxic agents, with improved efficacy and safety profiles.

In H1 2026, as part of the "ADCraft – next-generation small-molecule payloads for antibody-drug conjugates in oncology" Project (agreement no. 2024/ABM/05/KPO/KPOD.07.07-IW.07-0277/24), co-financed by the Medical Research Agency from the National Recovery and Resilience Plan (KPO) funds, Ryvu developed a methodological cascade for the selection and optimization of novel ADC payload molecules, enabling the characterization of several chemical series with the potential to become new payload classes. As a result of this work, the Company obtained an ADC conjugate with a novel payload exhibiting sub-nanomolar cellular activity and a profile differentiated from DXd and MMAE, the payload classes currently dominating the market as topoisomerase and microtubule inhibitors, respectively. The molecule targets a new, undisclosed biological target and has no direct competition on the market. The work initiated under the ADCraft Project is being continued from the Company's own resources. Further generations of payloads with an improved profile have been obtained, and the conjugates built on them demonstrated high antitumour activity in vitro and led to tumour regressions in a mouse xenograft model. These results form the basis for the work towards the selection of a lead payload candidate and novel ADCs.

STING agonist ADC collaboration with Exelixis

In July 2022, Ryvu signed a licensing agreement with Exelixis to collaborate on novel targeted therapies based on the advanced STING agonist technology developed at Ryvu. To date, under the terms of the collaboration, Ryvu has received a total of $3 million in milestone payments from Exelixis. The partnership has developed highly potent STING-activating antibody-drug conjugates that demonstrate picomolar in vitro activity and antigen-specific activation of the STING pathway; further development of these compounds is currently ongoing however progress on the project remains confidential.

BioNTech: Multi-target research collaboration

In November 2022, BioNTech and Ryvu initiated a comprehensive, multi-target research collaboration to advance small-molecule programs focused on immune modulation in cancer and potentially other disease areas. Under this partnership, BioNTech has the right to acquire global development and commercialization rights for these programs. While multiple research initiatives are underway as part of this collaboration, detailed information about these programs remains confidential.

2.2 Significant events affecting the Issuer's operations

2.2.1 During the reporting period

RVU120 update on Food and Drug Administration (FDA) Type C meeting regarding romaciclib (RVU120)

On January 16, 2026, the Company received the minutes of the Type C meeting with the U.S. Food and Drug Administration, which was held on January 13, 2026, regarding the component of the romaciclib (RVU120) development program related to its combination with venetoclax for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML) following failure of venetoclax in combination with a hypomethylating agent. This indication is currently being tested in the RIVER-81 study. The other indications in which romaciclib is being developed by Ryvu were not discussed at this meeting.

The purpose of the meeting, which was held at Ryvu's request, was to obtain the FDA's feedback on the further clinical development of romaciclib in patients with R/R AML in the United States, with respect to the observed benefit-risk profile. Ryvu also asked for guidance on dose optimization and design assumptions for future registrational clinical studies.

The FDA raised no objections to opening the expansion cohort in the United States with romaciclib at a dose of 150 mg once daily (QD- once a day) in combination with venetoclax, which was assessed in Cohort 4 of the RIVER-81 study.
At the same time, the FDA provided the Company with general guidance regarding:

- expectations related to dose optimization based on an integrated analysis of safety, pharmacokinetic, and pharmacodynamic data;
- clinical trial design for combination therapies, including the standard approach involving randomization in studies with registrational intent;
- the need for further clinical data generation prior to defining a registration pathway.

Next Steps
Following the FDA meeting, the Management Board of the Company plans to undertake the steps required to initiate the dose expansion of romaciclib at 150 mg QD in the United States, including:

- updating the RIVER-81 study protocol, including clarification of safety criteria and the rationale for dose and regimen selection;

- submission of updated documentation to the FDA under the existing Investigational New Drug (IND) application, in line with the feedback received;
- initiation of patient enrollment in the U.S. expansion cohort following completion of the above regulatory steps.

After obtaining more mature clinical data from the expansion stage, the Company plans to hold a subsequent regulatory meeting with the FDA to discuss the further clinical development strategy for the romaciclib program in the aforementioned regulatory pathway.

Conclusion of a grant agreement with the National Centre for Research and Development

On March 11th, 2026, the Company has concluded a grant agreement (the “Agreement”) with the National Centre for Research and Development (in Polish: Narodowe Centrum Badań i Rozwoju, “NCBR”) for the co-financing of the Company’s project entitled: “PERO - Predictive Engineering for Rational Oncology: functional mapping of therapeutic targets in oncology" ("Project"). The Agreement was concluded as a result of a call for proposals organized by the National Centre for Research and Development for entrepreneurs aimed at the development of critical technologies and technologies intended to protect and strengthen relevant critical technology value chains in the biotechnology sector under the European Funds for a Modern Economy Programme (FENG), Priority 5: Support for projects contributing to the objectives of the STEP initiative, FENG.05.01-IP.01-001/25 call - Track A: Projects implemented in the biotechnology sector.

The objective of PERO is to establish an innovative technological platform for the functional validation of structural protein pockets of potential therapeutic targets in oncology. The project addresses a significant technological gap by enabling an in-depth, currently unavailable level of functional target validation based on integrated genomic, structural, and pharmacological data.

- the total net value of the Project is: PLN 32,350,211.50;
- recommended amount of the funding: PLN 19,956,904.12;
- the planned duration of the Project: 51 months.

The funding granted under the Agreement will reduce the use of the Company's own funds.

Extension of the Research Collaboration Option and Exclusive License Agreement with BioNTech SE

On March 15, 2026, Ryvu and BioNTech SE, with its registered office in Mainz, Germany (“BioNTech”), have entered into Amendment No. 1 to the research collaboration option and exclusive license agreement dated November 29, 2022 (“License Agreement”). The Company disclosed the conclusion of the License Agreement in its Current Report No. 26/2022 dated November 30, 2022.
Under the Amendment, the parties agreed, among others, to extend the term of the research collaboration conducted under the License Agreement by an additional period of one year, i.e., until November 29, 2028.
The remaining key terms of the License Agreement, including the economic terms of the collaboration and BioNTech's funding of discovery, research, and development activities thereunder, remain unchanged.

Poster presenting preclinical data for the ONCO Prime platform at the AACR Annual Meeting 2026

On April 20, 2026, during the AACR Annual Meeting held on April 17–22, 2026 in San Diego, California, the Company presented preclinical data for the ONCO Prime platform.

Details on the poster presentation are as follows:

Abstract Title: "ONCO Prime platform enables discovery of synthetic lethal targets for genetically stratified cancers"
Poster Number: 2989
Session date and time: 20/04/2026, 2:00 PM - 5:00 PM EST

Colorectal cancer (CRC) remains a leading cause of cancer mortality, underscoring the need for new, mechanism-based therapeutic strategies. Using the ONCO Prime discovery and validation platform, based on genome-wide CRISPR/Cas9 screenings across clinically relevant models, we identified novel treatment options for genetically stratified CRC patients.

The ONCO Prime platform integrates healthy human intestinal stem cells (hISCs), isogenic CRC models carrying key driver mutations (*APC*, *KRAS*), and patient-derived primary cultures. All types of models can be genetically manipulated or used in the high-throughput setting for drug screening. Transcriptomic and machine learning analyses confirmed that these models faithfully recapitulate CRC molecular diversity and clinical behavior.

Systematic CRISPR/Cas9 loss-of-function screenings revealed multiple synthetic lethal (SL) interactions, uncovering target genes with first-in-class therapeutic potential. Additionally, using a clinical-grade drug that is FDA-approved in other indications, we achieved proof of concept in genetically stratified CRC models, demonstrating strong efficacy as monotherapy in vitro. These data validate ONCO Prime's translational capability to uncover clinically actionable vulnerabilities and deliver tangible therapeutic candidates.

This work provides a robust foundation for drug discovery programs and strategic partnerships built on ONCO Prime's ability to bridge functional genomics with therapeutic development. Our first proof of concept establishes ONCO Prime as a scalable platform to drive the next generation of precision, first-in-class oncology therapies.

The poster is now available online and can be obtained from the conference site: https://www.aacr.org/

Romaciclib development priorities update

The Management Board of Ryvu Therapeutics S.A. with its' registered office in Kraków, Poland ("Company", "Ryvu") announces development and financing priorities for romaciclib (RVU120).

Following an analysis of Company resources and clinical data generated so far, the Management Board of the Company decided to prioritize romaciclib's development on acute myeloid leukemia (AML), particularly in patients with relapsed/refractory AML following venetoclax-based regimens, which

represents the area of greatest unmet medical need and most compelling clinical data observed to date.

This approach is intended to preserve strategic optionality for romaciclib while, in the short term, focusing resources on the clinical dataset expected to be most relevant to potential development partners for romaciclib.

Current discussions with interested parties indicate that the optimal timing for a partnering transaction will follow the completion of the dose expansion in the RIVER-81 study with the 150 mg QD cohort. Accordingly, the Company plans to continue the RIVER-81 study by enrolling approximately 30 additional patients subject to regulatory clearances.

As part of resource prioritization, the Management Board of the Company decided to close the POTAMI-61 Phase II study investigating romaciclib for the treatment of patients with intermediate- or high-risk primary or secondary myelofibrosis (MF). Romaciclib demonstrated a favorable safety profile and clinical activity in MF, both as monotherapy and in combination with ruxolitinib. The observed spleen volume reductions and hematologic tolerability support continued clinical evaluation.

POTAMI-61 was initiated on December 4, 2024, as the Company informed in the Current Report ESPI 37/2024 dated December 5, 2024. Following completion of Part A (23 patients) and initial enrollment in Part B (5 patients), the Company has decided not to proceed with further enrollment, closing the study at 28 patients. Patients currently participating in the study and deriving clinical benefit from romaciclib according to the investigators' assessment will continue to receive treatment in a new rollover study (ROVER-01), in accordance with applicable regulatory and ethical requirements. The Company will analyze data from POTAMI-61 to inform potential future MF development decisions and retain the option to resume a modified MF development program.

In addition, the Company expects that the Investigator-Sponsored Trial in medulloblastoma (MEDWAY) at the Children's Memorial Health Institute in Warsaw will be initiated over the coming months.

Based on currently available information and existing development plans, the above decisions are not expected to have a material adverse impact on the Company's 2026 and 2027 financial outlook.

Clinical data on romaciclib presented at the 2026 European Hematology Association Congress

The Company has presented clinical data on romaciclib (RVU120) at the European Hematology Association Congress (EHA), June 11-14, 2026, in Stockholm, Sweden.

Program updates:

In the RIVER-81 trial of patients with r/r AML, Ryvu is initiating an expansion cohort of approximately 30 patients to confirm the positive efficacy demonstrated in the dose cohort of 150 mg QD romaciclib combined with 400 mg QD venetoclax, as the Company informed in the current report no. 9/2026 dated May 20, 2026. Following completion of the required regulatory steps, including an updated study protocol and submission of documentation under the existing IND, the FDA reactivated the IND for RIVER-81 study on May 28, 2026.

In the POTAMI-61 study investigating romaciclib's efficacy in MF, eight patients will be transferred into the ROVER-01 study rollover protocol, underscoring that a subset of patients continue to derive meaningful clinical benefit from romaciclib treatment. These patients will continue to receive treatment with romaciclib as long as they benefit in ROVER-01.

EHA poster presentations:

Poster (PF529): Updated findings from the Phase 2 **RIVER-81** study of romaciclib (RVU120) combined with venetoclax in acute myeloid leukemia after first-line venetoclax and hypomethylating agent failure

Poster session date and time: Friday, June 12 (6:45 - 7:45 PM CEST)

Venetoclax (VEN) combined with hypomethylating agents is the standard first-line treatment for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy, yet ~70% experience relapsed/refractory disease with a median survival of under three months. Romaciclib, a first-in-class CDK8/CDK19 inhibitor, has shown single-agent activity in AML and preclinical synergy with VEN through enhanced apoptotic signaling and attenuation of resistance pathways.

In the ongoing Phase 2 RIVER-81 trial, romaciclib in combination with VEN demonstrates anti-leukemic activity in patients with poor prognostic AML. While responses have been observed across dose levels, the most consistent responses were seen at romaciclib 150 mg QD + VEN 400 mg QD, including two complete remissions with (CR) and one without (CRi) full hematologic recovery, resulting in a CR/CRi rate of 43% (3/7). The mean duration of response (DoR) of the CRs was 156 days, reported with a cut-off date of 12 May 2026. Based on safety, PK, and preliminary efficacy findings, this regimen was selected as the recommended dose for expansion.

Poster (PS2008): Romaciclib (RVU120), a selective CDK8/19 inhibitor, as monotherapy or in combination with ruxolitinib in patients with myelofibrosis: Updated results from the phase II **POTAMI-61** study

Poster session date and time: Saturday, June 13 (6:45 - 7:45 PM CEST)

Myelofibrosis (MF) is driven by dysregulated JAK/STAT signaling, and while JAK inhibition with ruxolitinib (RUX) improves splenomegaly and symptoms, cytopenias and suboptimal responses remain clinical challenges. Romaciclib is a first-in-class, oral CDK8/19 inhibitor that modulates STAT-dependent transcription and shows synergy with RUX in preclinical MF models.

In the ongoing Phase II POTAMI-61 study, romaciclib administered as monotherapy or combined with RUX demonstrates a manageable safety profile in patients with MF without significant treatment-related cytopenias. Prolonged exposure, spleen volume reductions, including in patients with high-molecular-risk mutations, and favorable hematologic tolerability support continued clinical development.

The posters are available online and can be accessed via the conference website: https://ehaweb.org/ and Ryvu's website: https://ryvu.com/

Appointment of Supervisory Board Members of Ryvu Therapeutics S.A. for a new term of office

The Ordinary General Meeting of the Company has appointed, effective June 25th, 2026, the Supervisory Board Members of the Company for a new term of office, in the following composition:
1. Mr. Piotr Romanowski - Chairman of the Supervisory Board of the Company;
2. Mr. Tadeusz Wesołowski – Vice- Chairman of the Supervisory Board of the Company;
3. Mr. Rafał Chwast - Member of the Supervisory Board of the Company;
4. Mr. Scott Z. Fields - Member of the Supervisory Board of the Company;
5. Mr. Peter Smith - Member of the Supervisory Board of the Company.

Appointment of Management Board Members of Ryvu Therapeutics S.A. for a new term of office

The Supervisory Board of the Company has appointed, effective June 25th, 2026, the Management Board Members of the Company for a new 5-year term of office in the following composition:
1. Mr. Paweł Przewięźlikowski - President of the Management Board;
2. Mr. Krzysztof Brzózka - Vice-President of the Management Board;
3. Mr. Kamil Sitarz - Vice-President of the Management Board;
4. Mr. Hendrik Nogai - Member of the Management Board;
5. Ms. Justyna Żółtek - Member of the Management Board.

2.2.2. Events occurred between the end of the reporting period until the approval of the financial statement

Conclusion of an amendment to the global license agreement with Menarini Group concerning the further clinical development of dapolsertib

The Company has concluded with Berlin-Chemie AG, with its registered office in Berlin, Germany, a member of the Menarini Group (the “Menarini Group”), an amendment (the “Amendment”) to the global license agreement concerning dapolsertib, also known as MEN1703 and SEL24 (the “Agreement”).
Pursuant to the Amendment, Menarini Group will expand the clinical development of dapolsertib by initiating a new Phase II clinical study in patients with myelofibrosis, a rare hematological malignancy. The study will evaluate dapolsertib primarily as monotherapy. The decision to initiate the study is supported by preclinical data indicating activity of dapolsertib in myelofibrosis models.
The Company will act as sponsor of the study and will be responsible for its operational conduct on behalf of Menarini Group, including, in particular, study management, clinical monitoring, regulatory submissions, medical oversight and data management. Menarini Group will be responsible for funding all study activities covered by the Amendment in accordance with the agreed budgets, and the Company will receive full reimbursement of costs incurred in connection with the conduct of the study, in line with those budgets.

Dapolsertib is a selective, small-molecule, dual inhibitor of PIM and FLT3 kinases, two enzymes strongly implicated in the malignant transformation of hematopoietic cells. The compound has been discovered by the Company and is currently in clinical development in collaboration with Menarini, which holds global development and commercial rights to dapolsertib.

The conclusion of the Amendment is material for the further clinical development of the dapolsertib program, as it expands the program into a new indication, and defines the further scope of the Company's operational collaboration with Menarini Group.

Ryvu's project recommended for funding by the National Centre for Research and Development

On August 10th, 2026, following the acceptance of the appeal against the results of the evaluation of the funding application, the National Centre for Research and Development ("NCBR") included the Company's project entitled "PANACEA-NOVO - patient-oriented innovative targeted therapies for rare cancers" on the ranked list of projects recommended for funding under the call FENG.05.01-IP.01-001/26 - Projects of Polish enterprises designated as associated partners in the European Commission decision concerning IPCEI in an area relevant to the implementation of the STEP initiative. The call is conducted under the European Funds for a Modern Economy Programme (FENG), Priority 5 - Support for projects contributing to the objectives of the STEP initiative.

The objective of the PANACEA-NOVO project is to develop a unique technology platform for the discovery and validation of novel therapeutic targets with potential applications in the treatment of rare cancers for which effective, targeted treatment options are currently lacking. The platform will establish an integrated workflow from the oncology patient to the biological target and subsequently to the development of a targeted therapy.
- the total net value of the Project is: PLN 134,575,377.66;
- recommended amount of the funding: PLN 106,690,367.70;
- the planned duration of the Project: 58 months.

Ryvu launches a specialized early clinical development services business under the "Keelira" brand

On August 18, 2026, the Company launched a specialized early clinical development services business providing biotech and pharma companies with integrated services supporting the development of oncology programs across European markets.
The Company will provide these services under the dedicated "Keelira" brand, from preparation of programs for clinical entry through Phase I and Phase II development, with a particular focus on oncology, hemato-oncology and rare oncology indications. Keelira's service model combines Clinical Execution, Strategic Advisory and Central Lab services.
Keelira's operating model was developed within the Company to support the development of its own oncology pipeline and was subsequently applied in clinical collaborations with external international biotech and pharma companies. The purpose of launching Keelira is to commercialize the Company's existing clinical development capabilities and to develop a complementary revenue stream in a capital-efficient manner.
The Keelira services business has been designed to develop alongside the Company's core drug discovery and development activities. Accordingly, Keelira operates within Ryvu under a dedicated operating model and quality management system, with separate data-management arrangements and governance rules applicable to external clients. The development of the Company's own oncology pipeline remains its strategic priority.
The Keelira services business will be led by Kamil Sitarz, Vice-president of the Management Board and Chief Operating Officer of Ryvu Therapeutics, who will serve as General Manager of Keelira.

Recommendation of Ryvu's project for funding by the Polish Agency for Enterprise Development

On September 7th, 2026 the Company's project titled "DUALIS - technology platform for the discovery of next-generation bivalent ADC payloads" ("Project") has been placed on the ranked list of projects recommended for funding under the SMART Path call for entrepreneurs, organized by the Polish Agency for Enterprise Development ("PARP"). The call is implemented under the European Funds for a Modern Economy Programme (FENG), Priority 1: "Support for Entrepreneurs", FENG.01.01-IP.02-001/26 call.

The objective of DUALIS is to develop and implement an innovative DUALIS technology platform designed to accelerate and increase the efficiency of the discovery of next-generation bivalent payloads used in antibody-drug conjugates (ADC) in oncology. The platform is intended to enable the generation of new classes of payloads with complex, synergistic mechanisms of action, including those based on the simultaneous modulation of two biological targets and induced proximity mechanisms within a novel discovery process, thereby addressing significant limitations of currently used ADC technologies.

- the total net value of the Project is: PLN 30,860,980.64;
- recommended amount of the funding: PLN 22,245,183.62;
- the planned duration of the Project: 54 months.

2.3 Unusual events occurring in the reporting period

Not applicable.

3. THE ISSUER'S CORPORATE BODIES

Issuer's Management Board:

1) Paweł Przewięźlikowski – President of the Management Board
2) Krzysztof Brzózka – Vice President of the Management Board
3) Kamil Sitarz – Vice President of the Management Board
4) Vatnak Vat-Ho – Member of the Management Board until June 25, 2026.
5) Hendrik Nogai – Member of the Management Board
6) Justyna Żółtek – Member of the Management Board

Issuer's Supervisory Board :

1) Piotr Romanowski – Chairman of the Supervisory Board
2) Tadeusz Wesołowski – Vice Chairman of the Supervisory Board
3) Rafał Chwast – Supervisory Board Member
4) Axel Glasmacher – Supervisory Board Member until June 25, 2026.
5) Thomas Turalski – Supervisory Board Member until June 25, 2026.
6) Scott Z. Fields – Supervisory Board Member
7) Peter Smith – Supervisory Board Member

Issuer's Audit Committee:

1) Rafał Chwast – Chairman of the Audit Committee
2) Piotr Romanowski – Member of the Audit Committee
3) Tadeusz Wesołowski – Member of the Audit Committee

The Company's Remuneration Committee:

1) Piotr Romanowski – Chairman of the Remuneration Committee until June 25, 2026 and from July 14, 2026
2) Axel Glasmacher – Member of the Remuneration Committee until June 25, 2026
3) Thomas Turalski – Member of the Remuneration Committee until June 25, 2026
4) Scott Z. Fields – Member of the Remuneration Committee from July 14, 2026
5) Peter Smith - Member of the Remuneration Committee from July 14, 2026

4. INFORMATION ON THE SHAREHOLDERS HOLDING (DIRECTLY OR INDIRECTLY) AT LEAST 5% OF THE TOTAL NUMBER OF VOTES AT THE GENERAL SHAREHOLDERS' MEETING OF THE COMPANY AND ON SHARES HELD BY MEMBERS OF THE ISSUER'S MANAGEMENT BOARD AND SUPERVISORY BOARD

Shares held by members of the Management and Supervisory Board

Shares held by members of the Management and Supervisory Board of Ryvu Therapeutics S.A. as of June 30, 2026 and as of the date of publication of the Report

Shareholder	Preferred shares*	Ordinary shares	Number of shares	% of Share Capital	Number of Votes	% of Votes at SM
The Management Board						
Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)**	3 500 000	482 160	**3 982 160**	17,22%	**7 482 160**	27,54%
Krzysztof Brzózka		267 321	**267 321**	1,16%	**267 321**	0,98%
Kamil Sitarz		39 230	**39 230**	0,17%	**39 230**	0,14%
Hendrik Nogai		22 500	**22 500**	0,10%	**22 500**	0,08%
Justyna Żółtek		18 265	**18 265**	0,08%	**18 265**	0.07%
The Supervisory Board						
Tadeusz Wesołowski (directly)		92 975	**92 975**	0,40%	**92 975**	0,34%
Tadeusz Wesołowski* (indirectly through Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie)**		1 279 738	**1 279 738**	5,54%	**1 279 738**	4,71%
Rafał Chwast		121 115	**121 115**	0,52%	**121 115**	0,45%

**A single Series A share entitles to two votes at the Shareholder Meeting.*

***A beneficiary of Benevora Fundacja Rodzinna w organizacji is Mr. Paweł Przewięźlikowski – President of the Management Board*

****The beneficiary of Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie is Mr. Tadeusz Wesołowski - Vice-Chairman of the Supervisory Board.*

Shares held by significant shareholders of the Company

Shares held by significant shareholders of the Company as of June 30, 2026 and as of the date of the publication of the Report

Shareholder	Shares	% [Shares]	Votes	% [Votes]
Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)*	3 982 160	17,22%	7 482 160	27,54%
Bogusław Sieczkowski (through CapitalS Fundacja Rodzinna w organizacji)**	825 348	3,57%	1 375 348	5,06%
Tadeusz Wesołowski (with Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie)***	1 372 713	5,94%	1 372 713	5,05%
Nationale Nederlanden OFE	1 385 262	5,99%	1 385 262	5,10%
Allianz Polska OFE	2 292 540	9,92%	2 292 540	8,44%
BioNTech SE	1 917 437	8,29%	1 917 437	7,06%

** A beneficiary of Benevora Fundacja Rodzinna w organizacji is Mr. Paweł Przewięźlikowski*

***A beneficiary of CapitalS Fundacja Rodzinna w organizacji is Mr. Bogusław Sieczkowski*

****The beneficiary of Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie is Mr. Tadeusz Wesołowski*

The above information on the state of possession of the Issuer's shares by shareholders (including those being members of the Company's bodies) holding directly and indirectly at least 5% of the total number of votes at the Company's General Meeting has been prepared on the basis of information obtained from shareholders through their performance of duties imposed on shareholders of public companies by virtue of relevant legal regulations, including on the basis of the provisions of the Act of 29. July 2005 on public offering and the conditions for introducing financial instruments to the organized trading system and on public companies (art. 69 and art. 69a) and on the basis of the provisions of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directive 2003/124/EC, 2003/125/EC and 2004/72/EC (MAR Regulation, art. 19). In addition, information on the ownership of the Company's shares is provided on the basis of publicly available data on the portfolio exposure and asset structure of investment funds or pension funds, including information on the number of shares registered at the Company's General Meeting (data available periodically, inter alia, based on information from the financial statements of investment funds and pension funds - data may be subject to change since the date of publication of the last information).

5. MANAGEMENT BOARD STATEMENT ON ADOPTED ACCOUNTING PRINCIPLES

The management board of Ryvu Therapeutics S.A. confirms that, to the best of its knowledge, these interim condensed financial statements of Ryvu Therapeutics S.A. and comparative data have been prepared in accordance with the applicable accounting principles and reflect in a true, fair and clear manner the Company's property and financial position and its financial result.

The interim condensed report of the management board on the activities of Ryvu Therapeutics S.A. provides a true picture of the Company's development, achievements, and situation, including a description of the main threats and risks.

6. ADDITIONAL INFORMATION

Proceedings pending at court, before an arbitration institution or a public administration authority

The Company has filed a lawsuit against DUNA POLSKA S.A. (formerly: Mota-Engil Central Europe S.A.) ("Contractor") to the Regional Court in Kraków concerning the construction of the Research and Development Center under the agreement for "Construction of the Research and Development Center of Innovative Drugs Selvita S.A." dated August 13, 2018 ("Construction Agreement"). The claims include payment of contractual penalties for failure to meet the final and intermediate deadlines, as well as for rectification or untimely rectification of defects related to the scope of the Construction Agreement, totalling PLN 13,756,717.07. The total value of the Construction Agreement was PLN 68.783.585,34,, including VAT. The proceedings are taking place before the District Court in Kraków in the first instance. On July 8, 2024, the Court concluded the oral hearings of the witnesses and the Parties, simultaneously requiring the Parties to pay advances toward the expert's opinion (by July 22, 2024) and to inform the Court of the mutually agreed-upon candidates for experts (by September 1, 2024). The Parties responded to the Court's request within the above-mentioned deadlines. Subsequently, the Court requested the Parties to take a position on the offer of the expert selected by the Parties, who will prepare an opinion within the scope of the evidence outlined by the Parties. Both Parties accepted the offer. The files have been sent to an expert who will prepare an opinion based on the questions outlined by the Parties. The court has extended the deadline for preparing the opinion to July 30, 2026. As of the date of publication of the report, the opinion had not been submitted.

The Contractor has filed a lawsuit for payment against the Company to the District Court in Kraków in connection with the performance of the Construction Agreement for the project entitled: "Construction of the Research and Development Center for Innovative Drugs Selvita S.A." In the lawsuit, the Contractor is claiming damages for the costs incurred in connection with prolonged performance of the Construction Agreement, the unpaid portion of the lump sum fee as well as supplementary remuneration for additional, replacement and omitted works (PLN 5,391,425.63) as well as damages resulting from the Company's unauthorized - in the Contractor's opinion - application of the performance bond and removal of the defects and faults (PLN 2,063,507.56). With the statutory interests, the Contractor demands a total amount of PLN 7,671,285 from the Company. On November 22, 2023, the hearings of all witnesses and parties were completed. Subsequently, the files were forwarded to a court expert for the preparation of an opinion. On April 8, 2025, the expert's opinion was delivered to the Company, to which the Parties submitted objections in a procedural letter dated May 30, 2025. The expert responded to the objections and submitted an offer to prepare a supplementary opinion. Currently, the court has instructed the expert to prepare a supplementary report and has ordered that an advance payment be made to the expert for that purpose.

Significant non-arm's-length transactions with related entities

Not applicable.

Information on organizational or capital relations of the Issuer with other entities

As of the report's publication date, the Issuer does not form a Capital Group. As at the date of this Report, the Issuer holds 1.06% of shares in NodThera Inc.

Warranties for loans and borrowings and guarantees granted

Not applicable.

Other information significant for the assessment of the Issuer's position in the area of human resources, assets, cash flows, financial results and changes thereof and information significant for the assessment of the Issuer's ability to settle its liabilities

Not applicable.

Factors which, in the Issuer's opinion, will affect the results over at least the following quarter

The results of the subsequent quarters will depend primarily on the execution of the Company's strategy, which assumes in particular that the following business objectives will be met:

- Advancing romaciclib (RVU120) through Phase II clinical development in relapsed/refractory AML following failure of venetoclax-based regimens — an indication with significant unmet medical need and no approved standard of care — with the objective of generating the clinical data required to define a registration pathway and support potential partnering transactions; the Company continues to evaluate options for future romaciclib development in additional hematologic indications based on emerging data;
- Supporting clinical development of our partnered candidate, dapolsertib (MEN1703, SEL24) by Menarini Group;
- Strengthening Company's discovery pipeline and accelerating progress using first in class novel small molecule precision medicine approach via our proprietary ONCO Prime platform, as well as antibody-drug conjugates (ADCs) with novel payloads.;
- Achieving financial milestones in the existing R&D collaborations (i.e. BioNTech, Exelixis, Menarini);
- Growing Keelira, the Company's dedicated early clinical development services business launched in August 2026, by expanding its client portfolio, with the objective of establishing it as a capital-efficient, complementary revenue stream alongside the Company's own oncology pipeline;
- Advancing business development activities for fully owned programs, including romaciclib, involving structured discussions with potential partners regarding licensing, co-development, and option arrangements across multiple markets, with the objective of concluding a partnering transaction upon achievement of pre-specified clinical data milestones from the RIVER-81 expansion cohort.

Explanations regarding the seasonal or cyclical nature of the Issuer's operations in the reported period

Not applicable.

Information on inventory write-downs to the net realizable amount and reversal of such write-downs

Not applicable.

Information on impairment write-downs in respect of financial assets, tangible fixed assets, intangible assets or other assets and the reversal of such write-downs

Not applicable.

Information on the set-up, increase, utilization and reversal of provisions

Information on the changes in provisions for holidays and bonuses is provided in note 17 to the financial statements.

Information on deferred income tax provisions and assets

No significant changes.

Information on significant purchases or disposals of tangible fixed assets

No significant changes.

Information on significant liabilities in respect of purchases of tangible fixed assets

No significant changes.

Information on significant settlements resulting from court cases

Not applicable.

Error corrections relating to previous periods

Not applicable.

Information on changes in the economic situation and business conditions, which have a significant effect on the fair value of the entity's financial assets and financial liabilities

Not applicable.

Information on the failure to repay a loan or borrowing or a breach of significant terms and conditions of a loan agreement, with respect to which no corrective action had been taken by the end of the reporting period

Not applicable.

Information on changes in the method of valuation of financial instruments measured at the fair value

Not applicable.

Information on changes in the classification of financial assets due to a change in their purpose

Not applicable.

Information on the issue, redemption and repayment of non-equity and equity securities

Not applicable.

Information on dividends paid (or declared) in the total amount and per share, divided into ordinary and preference shares

Not applicable.

Events that occurred after the date for which the quarterly financial statements were prepared, not disclosed in these financial statements although they may have a significant effect on the Issuer's future financial results

Not applicable.

Information on changes in contingent liabilities or contingent assets that occurred after the end of the last financial year

Information on changes in contingent liabilities or contingent assets is provided in note 22 to the financial statements.

Other disclosures which may have a material impact on the assessment of the Issuer's financial position and results of operations

Not applicable.

Amounts and types of items affecting the assets, liabilities, equity, net profit/ (loss) or cash flows, which are unusual in terms of type, amount or frequency

Not applicable.

Krakow, September 15th, 2026

Dokument podpisany przez Paweł Tadeusz Przewięźlikowski
Data: 2026.09.15 10:43:27 CEST

Paweł Przewięźlikowski
President of the Management Board

Dokument podpisany przez Krzysztof Daniel Brzózka
Data: 2026.09.15 09:14:23 CEST

Krzysztof Brzózka
Vice-President of the Management Board

Dokument podpisany przez Kamil Sebastian Sitarz
Data: 2026.09.15 05:17:54 PDT

Kamil Sitarz
Vice-President of the Management Board

Signed by / Podpisano przez:
FRANZ HENDRIK DR. NOGAI
Date / Data: 2026-09-15 13:35

Hendrik Nogai
Management Board Member

Justyna Żółtek
Chairperson Officer
Management Board Member

Elektronicznie podpisany przez Justyna Katarzyna Żółtek
Data: 2026.09.15 13:04:23 +02'00'

Justyna Żółtek
Management Board Member

CONTACT

RYVU THERAPEUTICS

2 Sternbacha Street

30-394 Krakow, Poland

P: +48 12 314 02 00

GENERAL INQUIRIES

ryvu@ryvu.com

RYVU THERAPEUTICS